Company: INDP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001641172-25-023499
Chunk: 20

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 20
---
 time outstanding.

The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, may adversely affect the rights our common stockholders by, among other things:

| ● | restricting                                                                   
 dividends on the common stock;                                                |
| ● | diluting                                                                      
 the voting power of the common stock;                                         |
| ● | impairing                                                                     
 the liquidation rights of the common stock; or                                |
| ● | delaying                                                                      
 or preventing a change in control without further action by the stockholders. |

As a result of these or other factors, the issuance of preferred stock could have an adverse impact on the market price of our common stock. There is no current intention for us to issue any shares of preferred stock.

Private Placement Warrants

We issued to investors in the June 2025 Private Placement investor (i) pre-funded warrants to purchase 190,795 shares of our common stock and (ii) warrants to purchase up to an aggregate of 1,384,722 shares of common stock at an exercise price equal to $8.3024 per share (subject to standard adjustments for stock splits, stock dividend, rights offerings and pro rata distributions). We also issued to designees of the placement agent in the June 2025 Private Placement, placement agent warrants to purchase up to an aggregate of 83,083 shares of common stock at an exercise price equal to $8.3024 per share (subject to standard adjustments for stock splits, stock dividend, rights offerings and pro rata distributions).

Duration and Exercise Price

The pre-funded warrants have an exercise price of $0.01 per share while the investor warrants and the placement agent warrants have an exercise price of $8.3024 per share. All the warrants were exercisable upon issuance, and while the investor warrants and the placement agent warrants will expire five years following their issuance, the pre-funded warrants have no expiration date. The warrants contain standard adjustments to the exercise price including for stock splits, stock dividend, rights offerings and pro rata distributions.

| 17 |

Exercise Limitation

A holder (together with its affiliates) may not exercise any portion of the warrant to the extent that the holder would beneficially own more than 4.99% or 9.99%, depending on the individual investor, of the outstanding common stock immediately after exercise (the “Beneficial Ownership Limitation”), except that upon at least 61 days’ prior notice from the holder to us, the holder may increase the Beneficial Ownership Limitation